Literature DB >> 25862891

Clinical significance of CD155 expression in human pancreatic cancer.

Satoshi Nishiwada1, Masayuki Sho2, Satoshi Yasuda1, Keiji Shimada3, Ichiro Yamato1, Takahiro Akahori1, Shoichi Kinoshita1, Minako Nagai1, Noboru Konishi3, Yoshiyuki Nakajima1.   

Abstract

BACKGROUND/AIM: CD155 is expressed in many types of human cells and has diverse functions. We herein evaluated the clinical importance of CD155 in pancreatic cancer.
MATERIALS AND METHODS: We investigated CD155 expression in 134 patients with pancreatic cancer, and evaluated the correlations of CD155 with prognosis, tumor immunity and angiogenesis. Furthermore, CD155 functions were examined.
RESULTS: CD155 expression was abundant in pancreatic cancer tissues. Patients with high CD155 expression had poorer postoperative prognosis than those with low expression. Multivariate analysis indicated that CD155 expression had a significant independent prognostic value. Tumor CD155 expression inversely correlated with the presence of tumor-infiltrating lymphocytes. Furthermore, it significantly positively correlated with vascular endothelial growth factor expression and intra tumoral microvessel density. In addition, silencing of CD155 inhibited proliferation, and induced cell-cycle arrest at G2/M phase in pancreatic cancer cells.
CONCLUSION: CD155 may play a critical role through both immunological and non-immuno logical mechanisms in pancreatic cancer and may be a therapeutic target for this intractable malignancy. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CD155; angiogenesis; pancreatic cancer; prognostic factor; tumor immunity

Mesh:

Substances:

Year:  2015        PMID: 25862891

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  51 in total

1.  Anticancer activity of emodin is associated with downregulation of CD155.

Authors:  Liang Fang; Fang Zhao; Stephen Iwanowycz; Junfeng Wang; Sophia Yin; Yuzhen Wang; Daping Fan
Journal:  Int Immunopharmacol       Date:  2019-07-17       Impact factor: 4.932

2.  Recombinant poliovirus for cancer immunotherapy.

Authors:  Millena Prata Jammal; Márcia Antoniazi Michelin; Rosekeila Simões Nomelini; Eddie Fernando Candido Murta
Journal:  Ann Transl Med       Date:  2018-09

Review 3.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

4.  COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.

Authors:  Kyle Hansen; Sandeep Kumar; Kathryn Logronio; Sarah Whelan; Samir Qurashi; Hsin-Yuan Cheng; Andrew Drake; Margaret Tang; Patrick Wall; David Bernados; Ling Leung; Eran Ophir; Zoya Alteber; Gady Cojocaru; Moran Galperin; Masha Frenkel; Mark White; John Hunter; Spencer C Liang; Maya F Kotturi
Journal:  Cancer Immunol Immunother       Date:  2021-04-26       Impact factor: 6.968

5.  A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155.

Authors:  Bushra Husain; Sree R Ramani; Eugene Chiang; Isabelle Lehoux; Sairupa Paduchuri; Tia A Arena; Ashka Patel; Blair Wilson; Pamela Chan; Yvonne Franke; Athena W Wong; Jennie R Lill; Shannon J Turley; Lino C Gonzalez; Jane L Grogan; Nadia Martinez-Martin
Journal:  Mol Cell Proteomics       Date:  2019-07-15       Impact factor: 5.911

6.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 8.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

9.  CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Authors:  Xian-Yang Li; Indrajit Das; Ailin Lepletier; Venkateswar Addala; Tobias Bald; Kimberley Stannard; Deborah Barkauskas; Jing Liu; Amelia Roman Aguilera; Kazuyoshi Takeda; Matthias Braun; Kyohei Nakamura; Sebastien Jacquelin; Steven W Lane; Michele Wl Teng; William C Dougall; Mark J Smyth
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 10.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.